Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.

View in: PubMed

subject areas

Aged
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Biomarkers
Erlotinib Hydrochloride
Fallopian Tube Neoplasms
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Ovarian Neoplasms
Patient Selection
Peritoneal Neoplasms
Quinazolines
Safety
Survival Rate
Treatment Outcome
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2

authors with profiles

Ravi Salgia
Gini Fleming
Everett E. Vokes